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Background and aims: To investigate the potential indications and adverse effects of using the opioid antagonist
naltrexone to treat problem gamblers. Case presentation: The ﬁles of the 1,192 patients who were referred to the
National Problem Gambling Clinic between January 2015 and June 2016 were audited. Seventeen patients were
considered appropriate for treatment with naltrexone, having attended and failed to respond to psychological
therapies at the clinic. Fourteen patients were placed on a regimen of 50 mg/day naltrexone. Discussion: Of the 14
patients who were treated with naltrexone, there were 10 for whom sufﬁcient follow-up existed to analyze the
treatment efﬁcacy and side effects of naltrexone. Patients showed signiﬁcant decreases in their craving to gamble and
the majority (60%) were able to abstain completely from gambling in the treatment period, with a further 20%
reducing their gambling to almost nothing. The reported side effects from the naltrexone included: loss of appetite,
gastrointestinal pain, headaches, sedation, dizziness, and vivid dreams. Two patients with concurrent alcohol-use
disorder relapsed during the treatment. One patient relapsed after the treatment period. Conclusions: The study
showed signiﬁcant outcomes in reducing gambling cravings for the sample set. Given the design of the study as a case
series, there was no control group, and a number of patients were on other psychotropic medications. We recommend
care when prescribing to those suffering from concurrent alcohol-use disorder.
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BACKGROUND
Pathological and problem gambling (PG) is a psychiatric
disorder characterized by persistent and recurrent gambling
behavior leading to clinically signiﬁcant impairment or
distress (American Psychiatric Association, 2013). Sufferers
tend to become increasingly involved in terms of time and
ﬁnancial commitment, continuing to gamble regardless of
the impact on their personal, social, and ﬁnancial well-being
(Hodgins, Stea, & Grant, 2011). There is a lack of remission
in PG, despite psychological intervention. PG is known to
have a negative impact on physical and mental health,
occupation, ﬁnancial matters, and interpersonal relation-
ships (Grant & Kim, 2001). There is a signiﬁcant relation-
ship between PG and comorbid psychiatric disorders, where
they are likely to have a mutually reinforcing effect on the
sufferer. Attempted or completed suicide is not uncommon
(Ledgerwood & Petry, 2004).
The UK Gambling Commission (2017) reported that, as
of December 2016, 48% of people had participated in
gambling in the past 4 weeks, an increase from 43% in
December 2015. The commission reported that 0.7% of
respondents identiﬁed as problem gamblers, amounting to
there being around 300,000 problem gamblers in the UK at
any one time. Those in the 18- to 24-year-old-age group are
least likely to gamble, with 33% reporting having partici-
pated in the past 4 weeks, versus 54% for the highest
participant group (45–54 years old people). However, these
young gamblers are almost twice as likely to be a problem
gambler, with 1.1% estimated to be so. Framing National
Health Service (NHS) treatment policy is particularly im-
portant, provided the risks of this vulnerable group and the
ease of accessing gambling online. It is one of the aims of
this study to help in guiding such policy.
Naltrexone is a US Food and Drug Administration
(FDA)- and National Institute for Health and Care Excel-
lence (NICE)-approved treatment for alcohol and opiate
dependence (Center for Substance Abuse Treatment,
2009). In preclinical data, naltrexone is advocated to help
treat addictions more diversely by blocking binding of
endogenous opioids. The suggested role of gambling in the
stimulation of the endogenous opioid system forms the
clinical basis for using opioid antagonists in the treatment
of PG (Grant, Odlaug, & Schreiber, 2014). Indeed, this is the
basis of its use in behavioral addictions more broadly
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(Grant, Schreiber, & Odlaug, 2013). In a randomized con-
trolled trial on kleptomania, it was found that subjects
randomized to receive naltrexone reported signiﬁcant reduc-
tions in urges in stealing and stealing behavior (Grant, Kim,
& Odlaug, 2009). A case series looking at compulsive
buying found that high-dose naltrexone led to partial or
complete remission of urges to shop (Grant, 2003). A
systematic review of the use of naltrexone in diverse
behavioral addictions showed consistent efﬁcacy of the
drug (Aboujaoude & Salame, 2016).
The body of literature on the pharmacological treatment
of PG is supportive of the use of opioid antagonists as a
treatment of “last resort” once psychological interventions
have failed. Grant et al. (2014) reviewed 18 randomized
control trials across ﬁve drug classes in the treatment of PG.
Antidepressants, mood stabilizers, and atypical antipsycho-
tics have shown mixed results, and there is no evidence to
recommend their use as a treatment protocol in PG. The
literature demonstrates a higher treatment efﬁcacy with
opioid antagonists (Grant, Kim, & Odlaug, 2007). The
earliest clinical indication for using naltrexone in PG came
from a single case report of a pathological gambler with a
13-year history of alcohol dependence. Signiﬁcant reduc-
tions in scores measuring compulsive drinking and compul-
sive gambling were observed (Crockford & el-Guebaly,
1998). We reviewed the evidence from three randomized
control trials that speciﬁcally looked at the efﬁcacy of daily
naltrexone in PG (Kim & Grant 2001; Kim, Grant, Adson,
& Shin, 2001; Grant, Kim, & Hartman, 2008), ﬁnding
signiﬁcant reductions in gambling outcomes in all three.
We also reviewed two “as needed” (pro re nata) studies
(Lahti, Halme, Pankakoski, Sinclair, & Alho, 2010;
Kovanen et al., 2016), ﬁnding more mixed results. For
completeness, we reviewed studies of another opioid antago-
nist, nalmefene. Grant et al. (2006) showed signiﬁcant reduc-
tions in gambling urges; however, a later trial suggested that
only those patients on high doses reported reductions in the
primary outcome measure (Grant, Odlaug, Potenza,
Hollander, & Kim, 2010). It was on this basis that it was
decided to treat our patients with a daily dose of naltrexone.
To date, there has been no research performed in the UK
on the use of naltrexone in PG. There have been no NICE
guidelines for the treatment of PG; thus, as elsewhere, UK
clinicians have been referring to the Monash guidelines.
According to GambleAware, only 2.7% of those affected by
PG are in treatment at any one time, compared with 6% of
problem drinkers and 50% of Class A drug misusers. Given
the psychosocial and medical impact of PG, we believe that
parity of esteem in its treatment with other mental health
issues is required, including in pharmacological interven-
tion. As such, we saw value in a case series discussion for
patients who had been pharmacologically treated with nal-
trexone in the UK. Our ﬁndings add credibility to the
international evidence base on the pharmacological treat-
ment of PG, which is still limited.
The pharmacokinetic safety of naltrexone indicates that it
is a well-tolerated drug, with transient and self-limiting side
effects (Foss et al., 1997). Naltrexone is known to cause
overdose symptoms, if used simultaneously as opioids. The
British National Formulary notes that naltrexone is contra-
indicated in patients suffering from hepatic or renal
impairment (Joint Formulary Committee, 2015). These are
important areas of clinical monitoring.
CASE PRESENTATION
The case series was performed through a retrospective audit
of the case ﬁles of the 1,192 patients who attended the
National Problem Gambling Clinic in the 18-month period
between January 2016 and June 2017. Five hundred and
sixteen of these patients entered treatment, of which 17 were
screened as appropriate for treatment with naltrexone.
Naltrexone was indicated for severely affected patients,
as measured by the Problem Gambling Severity Index
(PGSI). These patients had already undergone psychologi-
cal therapy for PG at the National Problem Gambling Clinic
(NPGC) with limited success. The severity of their craving
to gamble was measured again at the naltrexone assessment
using the Gambling Craving Scale (GCS). It was conﬁrmed
at this stage that the patient was committed to either abstain
from or dramatically reduce their gambling behavior. Only
patients with normal liver and renal function tests and who
would be able to avoid abuse of alcohol throughout the
treatment period were considered. Patients with an existing
recreational or prescription use of opiates were also exclud-
ed, due to the risk of overdose. Out of the 17 patients, 14 had
commenced treatment.
The treatment commencement dates for the patients in
the sample set fell between January 2016 and April 2017.
Patients were prescribed an initial dose of 25 mg per day for
3 days, and then 50 mg per day as the usual maintenance
dose. Details of other support services, such as Gamblers
Anonymous, as well as information on the potential side
effects of naltrexone were provided to the patients. Any
patient-reported side effects or unintended treatment out-
comes of the naltrexone were recorded.
Patients were called for follow-up after 6 weeks, where a
further GCS was answered as well as a reﬂective question-
naire on the patient’s experience of treatment. If the treatment
suited the patient, a further prescription of the maintenance
dose was offered for 8 weeks, after which prescribing was
handed-over to the patient’s general practitioner.
Of the 14 cases, there were 10 for whom sufﬁcient
follow-up existed to enable a meaningful analysis of the
efﬁcacy of their treatment. These patients are summarized in
Table 1. The information considered adequate was the
presence of a complete psychosocial and forensic history,
information on comorbidities and other addictions, gam-
bling history, history of past treatment modalities, a cor-
rectly completed GCS for both prior to and 6 weeks
following commencement of treatment with naltrexone, and
the reﬂective questionnaire. There were a further two cases
for whom answers to the reﬂective questionnaire were
available. We comment on the responses to this question-
naire at the end of the discussion.
Of the 10 patients, 8 were male and 2 were female. The
ages of the patients ranged from 29 to 56 years, with a
median age of 44 years. These patients had gambling careers
spanning from 3 to 40 years, with a median career length of
21 years. The patients reported estimated total losses (ETLs)
of between £5,000 and £1,700,000, with the majority having
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signiﬁcant personal indebtedness as a consequence of their
losses. The average ETL was £459,375. All of the patients
had already completed, or attempted to complete a previous
gambling-speciﬁc treatment modality. These modalities in-
cluded self-exclusion, GamCare counselling, Gamblers
Anonymous, and Gordon Moody. All patients had attended
a previous NPGC psychotherapy or cognitive behavioral
therapy program. The responses to the PGSI before the
commencement of naltrexone ranged from 12/27 to 27/27,
with a median score of 21.5. For eight patients, the treatment
goal was abstinence and for two it was reduction.
Eight of the 10 patients reported diagnosis of an axis I
psychiatric disorder, including schizophrenia, bipolar
affective disorder, attention deﬁcit hyperactivity disorder
(ADHD), depressive disorder, or a concurrent addictive
pathology. Six patients were taking another psychotropic
medication, which included antidepressants and
antipsychotics. Four patients reported a chronic medical
comorbidity. All 10 patients had signiﬁcant social
history including family breakdown, previous emotional
or sexual abuse by a close friend or family member,
family history of an axis I disorder, unemployment, time
spent in care as a child, and homelessness. Four of the
patients had a history of illegal activity in order to fund
their gambling.
The reported side effects of the naltrexone were loss of
appetite, gastrointestinal pain, sedative symptoms or feeling
“spaced out,” headaches, nausea, dizziness, and vivid
dreams. The majority of side effects resolved within the
ﬁrst week. Unintended treatment outcomes included re-
duced anger, reduced impulsiveness, improvement in mood,
improved concentration, less compulsion to overexercise,
less interest in overeating, and increased calmness.
As demonstrated in Table 1, all 10 patients experienced a
reduction in cravings to gamble as tested by the pre- and
post-commencement GCS. Responses to the pre-
commencement GCS ranged from 7/30 to 30/30, with a
median score of 27, making the median patient at “very high
risk” of gambling. Responses to the 6-week follow-up GCS
ranged from 0/30 to 17/30, with a median score of 5.5,
representing a “low risk” of gambling. Of the 10 patients, 6
were able to abstain completely for the whole treatment
period. Of the four who did not abstain, gambling behavior
was much reduced in two cases. Two patients relapsed. One
had a relapse of alcoholism and failed to continue taking the
naltrexone. One was experiencing intrusive side effects,
decided they could not forsake heavy drinking and was
advised to stop taking the naltrexone as a result. One patient
was reported to have relapsed after being discharged at the
end of the treatment period.
The reﬂective questionnaire of the 12 naltrexone-
consumed patients provided further color on the treatment
response:
• 11 said they had gambled less since started consuming
naltrexone.
• 10 said they had experienced less gambling-related
thoughts and urges.
• 8 said they had experienced side effects.
• 10 said it had not been difﬁcult to stick to the treatment.
Of those answering “yes,” one had found it hard to
abstain from opiate-based painkillers and one found it
hard to avoid alcohol-binges as well as struggling with
the side effects.
• When asked whether there had been any overall impact
on their day-to-day life, four cited a positive effect, one
a mixed effect, one speciﬁed that they had experienced
an effect but did not specify any details, and six
reported no impact.
• All 12 said they would recommend naltrexone to
someone else facing gambling difﬁculties.
Ethics
The study procedures were carried out in accordance with
the Declaration of Helsinki. All subjects were informed
about the study and provided informed consent.
DISCUSSION
The patient set was small and heterogeneous in terms of
presenting comorbidities, concurrent medication, and psy-
chosocial history, yet we observed marked improvement in
craving-to-gamble in all cases. In the context of the literature
to date, we view that our results with this sample of patients
from the NPGC give support of the use of naltrexone as an
adjunct treatment in PG.
We were not able to control for the presence of comor-
bidities and other psychotropic medications. We were not
able to comment on the effect of dosage, given that each
patient was given the same treatment regimen. However, the
review of Grant et al. (2008) suggested that 50 mg/day was
as efﬁcacious in treating PG as higher doses, which was the
basis of the decision to use 50 mg/day in the study. We were
not able to provide any evidence of the effect of naltrexone
on gambling urges and behavior following cessation of
treatment, although a 12-month follow-up study showed
that the majority (60%) of patients did not relapse within
6 months of stopping naltrexone (Dannon, Lowengrub,
Musin, Gonopolsky, & Kotler, 2007). There is a scope for
a randomized control trial over a longer period of time to
ascertain long-term treatment outcomes and the tolerability
of the treatment medically and psychologically, especially
once cessation has occurred.
To date, although evidence suggests that naltrexone has
the most potential as a pharmacological treatment for PG,
there has been no formal comparison study of its efﬁcacy
vis-à-vis other opioid antagonists in PG, notably nalmefene.
A comparative study of naltrexone and nalmefene was
conducted by Drobes, Anton, Thomas, and Voronin
(2003), testing their respective effects on alcohol consump-
tion, showing that the efﬁcacy was similar to each medica-
tion. The results suggested that the side effect burden was
lesser in the case of naltrexone. Once opioid antagonists are
established as a treatment modality for PG, a comparative
study between the two drugs for speciﬁc efﬁcacy in PG
would be worthwhile.
We found that alcohol consumption seemed to increase
the treatment resistance of a patient’s PG, based upon the
relapses of the heavy drinkers in the sample set. Baron and
Dickerson (1999) found that alcohol consumption signiﬁ-
cantly increases impairment in control of gambling
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behavior. Further work to investigate this relationship would
be useful in order to inform treatment protocol for PG
suffers who also drink heavily.
We believe that NICE guidelines are now required to
address a pathology that affects almost half a million people
in the UK, but that has not been given parity of esteem with
other mental health disorders by the NHS. The introduction
of naltrexone as a “last resort” treatment for those who have
been resistant to psychological therapies seems logical,
given its approval by both the FDA and NICE for other
addictive pathologies and the beneﬁts it has shown for PG in
the evidence, to date, further supported by our work at the
NPGC.
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